FDA Approved: REXULTI — Supplemental Application (Otsuka America Pharmaceutical, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Rexulti (brexpiprazole) from Otsuka America Pharmaceutical, Inc., under NDA 205422.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Schizophrenia

Drugs mentioned

• REXULTI (brexpiprazole)

Snippet

SUPPL AP for REXULTI (BREXPIPRAZOLE)